179 related articles for article (PubMed ID: 35579862)
1. Outpatient administration of naxitamab in combination with granulocyte-macrophage colony-stimulating factor in patients with refractory and/or relapsed high-risk neuroblastoma: Management of adverse events.
Mora J; Chan GC; Morgenstern DA; Nysom K; Bear MK; Tornøe K; Kushner BH
Cancer Rep (Hoboken); 2023 Jan; 6(1):e1627. PubMed ID: 35579862
[TBL] [Abstract][Full Text] [Related]
2. Guidelines for outpatient administration of naxitamab: Experience from Atrium Health Levine Children's Hospital.
Trovillion EM; Michael M; Jordan CC; Brown L; Phillips K; Oesterheld J; Saulnier-Sholler G
Cancer Med; 2024 Feb; 13(3):e7045. PubMed ID: 38396377
[TBL] [Abstract][Full Text] [Related]
3. How we approach the treatment of patients with high-risk neuroblastoma with naxitamab: experience from the Hospital Sant Joan de Déu in Barcelona, Spain.
Castañeda A; Gorostegui M; Miralles SL; Chamizo A; Patiño SC; Flores MA; Garraus M; Lazaro JJ; Santa-Maria V; Varo A; Muñoz JP; Mora J
ESMO Open; 2022 Apr; 7(2):100462. PubMed ID: 35397431
[TBL] [Abstract][Full Text] [Related]
4. Naxitamab: First Approval.
Markham A
Drugs; 2021 Feb; 81(2):291-296. PubMed ID: 33616889
[TBL] [Abstract][Full Text] [Related]
5. Naxitamab: a humanized anti-glycolipid disialoganglioside (anti-GD2) monoclonal antibody for treatment of neuroblastoma.
Slatnick LR; Jimeno A; Gore L; Macy ME
Drugs Today (Barc); 2021 Nov; 57(11):677-688. PubMed ID: 34821881
[TBL] [Abstract][Full Text] [Related]
6. Naxitamab combined with granulocyte-macrophage colony-stimulating factor as consolidation for high-risk neuroblastoma patients in complete remission.
Mora J; Castañeda A; Gorostegui M; Santa-María V; Garraus M; Muñoz JP; Varo A; Perez-Jaume S; Mañe S
Pediatr Blood Cancer; 2021 Oct; 68(10):e29121. PubMed ID: 34022112
[TBL] [Abstract][Full Text] [Related]
7. Novel infusion strategy reduces severe adverse events caused by the anti-GD2 monoclonal antibody naxitamab.
Varo A; Castañeda A; Chamorro S; Muñoz JP; Gorostegui M; Celma MS; Lopez S; Simao M; Perez-Jaume S; Mora J
Front Oncol; 2023; 13():1164949. PubMed ID: 37213300
[TBL] [Abstract][Full Text] [Related]
8. Humanized 3F8 Anti-GD2 Monoclonal Antibody Dosing With Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Resistant Neuroblastoma: A Phase 1 Clinical Trial.
Kushner BH; Cheung IY; Modak S; Basu EM; Roberts SS; Cheung NK
JAMA Oncol; 2018 Dec; 4(12):1729-1735. PubMed ID: 30326045
[TBL] [Abstract][Full Text] [Related]
9. Multidisciplinary Clinical Care in the Management of Patients Receiving Anti-GD2 Immunotherapy for High-Risk Neuroblastoma.
Cabral J; Fernandez EI; Toy B; Secola R
Paediatr Drugs; 2023 Jan; 25(1):13-25. PubMed ID: 36434427
[TBL] [Abstract][Full Text] [Related]
10. GM-CSF, G-CSF or no cytokine therapy with anti-GD2 immunotherapy for high-risk neuroblastoma.
Mora J; Modak S; Kinsey J; Ragsdale CE; Lazarus HM
Int J Cancer; 2024 Apr; 154(8):1340-1364. PubMed ID: 38108214
[TBL] [Abstract][Full Text] [Related]
11. Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial.
Mody R; Naranjo A; Van Ryn C; Yu AL; London WB; Shulkin BL; Parisi MT; Servaes SE; Diccianni MB; Sondel PM; Bender JG; Maris JM; Park JR; Bagatell R
Lancet Oncol; 2017 Jul; 18(7):946-957. PubMed ID: 28549783
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy with anti-G
Kushner BH; Modak S; Kramer K; Basu EM; Iglesias-Cardenas F; Roberts SS; Cheung NV
Int J Cancer; 2023 Jan; 152(2):259-266. PubMed ID: 35913764
[TBL] [Abstract][Full Text] [Related]
13. Naxitamab Combined with Granulocyte-Macrophage Colony-Stimulating Factor as Consolidation for High-Risk Neuroblastoma Patients in First Complete Remission under Compassionate Use-Updated Outcome Report.
Mora J; Castañeda A; Gorostegui M; Varo A; Perez-Jaume S; Simao M; Muñoz JP; Garraus M; Larrosa C; Salvador N; Lavarino C; Krauel L; Mañe S
Cancers (Basel); 2023 Apr; 15(9):. PubMed ID: 37174002
[TBL] [Abstract][Full Text] [Related]
14. Toxicity Spectrum of Anti-GD2 Immunotherapy: A Real-World Study Leveraging the US Food and Drug Administration Adverse Event Reporting System.
Wang G; Wang J; Du R; Wang Y; Li Z
Paediatr Drugs; 2024 Mar; 26(2):175-185. PubMed ID: 38153627
[TBL] [Abstract][Full Text] [Related]
15. Early Salvage Chemo-Immunotherapy with Irinotecan, Temozolomide and Naxitamab Plus GM-CSF (HITS) for Patients with Primary Refractory High-Risk Neuroblastoma Provide the Best Chance for Long-Term Outcomes.
Muñoz JP; Larrosa C; Chamorro S; Perez-Jaume S; Simao M; Sanchez-Sierra N; Varo A; Gorostegui M; Castañeda A; Garraus M; Lopez-Miralles S; Mora J
Cancers (Basel); 2023 Oct; 15(19):. PubMed ID: 37835531
[TBL] [Abstract][Full Text] [Related]
16. Pain mitigation and management strategies for anti-GD2 infusions: An expert consensus.
Nysom K; Morad AG; Rafael MS; Zier J; Marachelian A; Watt T; Morgenstern DA
Pediatr Blood Cancer; 2023 May; 70(5):e30217. PubMed ID: 36772891
[TBL] [Abstract][Full Text] [Related]
17. Dinutuximab for maintenance therapy in pediatric neuroblastoma.
McGinty L; Kolesar J
Am J Health Syst Pharm; 2017 Apr; 74(8):563-567. PubMed ID: 28389455
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of ch14.18 with granulocyte-macrophage colony-stimulating factor and interleukin-2 in children with neuroblastoma after autologous bone marrow transplantation or stem-cell rescue: a report from the Children's Oncology Group.
Gilman AL; Ozkaynak MF; Matthay KK; Krailo M; Yu AL; Gan J; Sternberg A; Hank JA; Seeger R; Reaman GH; Sondel PM
J Clin Oncol; 2009 Jan; 27(1):85-91. PubMed ID: 19047298
[TBL] [Abstract][Full Text] [Related]
19. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
20. Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial.
Ladenstein R; Pötschger U; Valteau-Couanet D; Luksch R; Castel V; Yaniv I; Laureys G; Brock P; Michon JM; Owens C; Trahair T; Chan GCF; Ruud E; Schroeder H; Beck Popovic M; Schreier G; Loibner H; Ambros P; Holmes K; Castellani MR; Gaze MN; Garaventa A; Pearson ADJ; Lode HN
Lancet Oncol; 2018 Dec; 19(12):1617-1629. PubMed ID: 30442501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]